Evaluating determinants of receipt of molecular imaging in biochemical recurrent prostate cancer-Reference-Cited by-同舟云学术

Evaluating determinants of receipt of molecular imaging in biochemical recurrent prostate cancer

Published:2020-11-28 Issue:1 Volume:10 Page:62-69
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med.

Author:

Borno Hala T.¹^ORCID,Kuo Lin Tracy²,Odisho Anobel Y.³⁴^ORCID,Desai Arpita¹,Koshkin Vadim¹,Werner Kalin⁵,Legaspi Nichole¹,Bucknor Matthew⁶,Bell Alexander⁷^ORCID,Zhang Sylvia¹,Hope Thomas A.⁶

Affiliation:

1. Department of Medicine Division of Hematology/Oncology University of California San Francisco San Francisco CA USA

2. Department of Social and Behavioral Sciences Institute for Health & AgingUniversity of California San Francisco San Francisco CA USA

3. Department of Urology University of California San Francisco San Francisco CA USA

4. Center for Digital Health Innovation University of California San Francisco CA USA

5. Division of Emergency Medicine University of Cape Town Cape Town South Africa

6. Department of Radiology and Biomedical Imaging University of California San Francisco San Francisco CA USA

7. School of Medicine University of California San Francisco San Francisco CA USA

Funder

Prostate Cancer Foundation

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3555

Reference21 articles.

1. Biochemical recurrence after radical prostatectomy: what does it mean?

2. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference

3. Novel Tracers and Their Development for the Imaging of Metastatic Prostate Cancer